Front Endocrinol (Lausanne)
January 2024
Introduction: The radioiodine-refractory (RAI-R) recurrent papillary thyroid carcinomas (PTCs) are more frequent in elderly patients and have an unfavorable prognosis. Data on the prevalence and characteristics of RAI-R recurrent PTCs in patients of young and middle age with or without a history of radiation exposure in childhood are poorly described. The aim of the current study was: i) to determine the frequency of RAI-R recurrent PTCs among donors of the Chornobyl Tissue Bank (CTB) and analyze the clinicopathological features of primary tumors (PTs), primary metastases (PMTSs), recurrent metastases (RMTSs) and risk factors for RMTS, and ii) to determine the immune checkpoint status (ICS) of the RAI-R recurrent PTCs and to assess the factors associated with ICS positivity.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
January 2023
Front Endocrinol (Lausanne)
September 2022
The potential overtreatment of patients with papillary thyroid microcarcinoma (MPTC) has been an important clinical problem in endocrine oncology over the past decade. At the same time, current clinical guidelines tend to consider prior radiation exposure as a contraindication to less extensive surgery, even for low-risk thyroid carcinomas, which primarily include microcarcinomas. This study aims to determine whether there are differences in the behavior of MPTC of two etiological forms (radiogenic and sporadic), including invasive properties, clinical data, and recurrence in patients aged up to 30 years.
View Article and Find Full Text PDFFront Med (Lausanne)
April 2022
With time after the Chernobyl accident, the number of papillary thyroid carcinomas (PTCs) driven by the BRAF oncoprotein is growing in patients exposed to radiation at a young age. Clinicopathological associations of BRAF in PTCs from patients with internal radiation history have not been sufficiently studied so far. This work analyzes the structural characteristics, proliferative activity, invasive features, clinical information, and dosimetric data in the BRAF-positive and BRAF-negative PTCs from the Ukrainian patients exposed to Chernobyl radiation and treated over 30 years after the accident.
View Article and Find Full Text PDF